3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Multiple Myeloma
2
Lymphoma
2
Sarcoma
1
Preleukemia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Osteosarcoma
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Myelodysplastic Syndromes
1
Mobility Limitation
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphatic Diseases
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphoid
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Interventions
lutetium Lu 177 dotatate
12
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
cabozantinib
5
Everolimus
5
pembrolizumab
4
Nivolumab
4
olaparib
3
lenvatinib
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
tivozanib
1
surufatinib
1
repotrectinib
1
peposertib
1
pazopanib
1
entrectinib
1
belinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Patient Reported Outcome Measures
×
90 days
×
Clear all
No trials found.